(Q30300986)

6 October 2017

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma (English)

1 reference

6 October 2017

1 reference

1 reference

ChEBI release 2020-05-28

1 reference

2

David A Reardon

1 reference

6 October 2017

20

Patrick Y Wen

1 reference

6 October 2017

1

Eudocia Q Lee

1 reference

6 October 2017

5

Alona Muzikansky

1 reference

6 October 2017

9

Rameen Beroukhim

1 reference

6 October 2017

18

Keith L Ligon

1 reference

6 October 2017

8

Lakshmi Nayak

1 reference

6 October 2017

10

Mikael L Rinne

1 reference

6 October 2017

7

Andrew D Norden

1 reference

6 October 2017

12

Tracy T Batchelor

1 reference

6 October 2017

16

Sarah C Gaffey

1 reference

6 October 2017

4

Jan Drappatz

1 reference

6 October 2017

14

Christine McCluskey

1 reference

6 October 2017

Katrina Smith Korfmacher

series ordinal

15

object named as

Katrina H Smith

1 reference

6 October 2017

6

Sean A Grimm

1 reference

6 October 2017

13

Kelly Hempfling

1 reference

6 October 2017

17

Brendan Wrigley

1 reference

6 October 2017

19

Jeffrey J Raizer

1 reference

6 October 2017

David Schiff

3

1 reference

6 October 2017

Andrew S Chi

series ordinal

11

1 reference

6 October 2017

language of work or name

1 reference

7 January 2015

1 reference

6 October 2017

1 reference

6 October 2017

17

1 reference

6 October 2017

6

1 reference

6 October 2017

862-867

1 reference

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483124

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483124

Profile of panobinostat and its potential for treatment in solid tumors: an update

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483124

HDAC inhibitor-based therapies: can we interpret the code?

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483124

Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483124

Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483124

Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483124

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483124

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483124

Novel anti-angiogenic therapies for malignant gliomas

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483124

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483124

Malignant gliomas in adults

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483124

Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483124

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483124

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483124

Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483124

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483124

The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483124

A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483124

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

3 June 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU350

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU350

Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU350

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU350

Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU350

Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU350

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU350

Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU350

21 January 2018

Identifiers

DOI

10.1093/NEUONC/NOU350

1 reference

6 October 2017

1 reference

6 October 2017

1 reference